A Phase 1, Randomized, Open-label, 2-way Crossover Study in Healthy East Asian and Caucasian Volunteers to Evaluate the Relative Bioavailability of A New Capsule Formulation of TG-2349 Compared to the Original Formulation of TG-2349 Oral Solution
Phase of Trial: Phase I
Latest Information Update: 30 Dec 2014
Price : $35 *
At a glance
- Drugs Furaprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors TaiGen Biotechnology
- 18 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Nov 2014 Planned End Date changed from 1 Dec 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 27 Nov 2014 Planned primary completion date changed from 1 Dec 2015 to 1 May 2014 as reported by ClinicalTrials.gov record.